皿治林治疗慢性荨麻疹临床疗效观察
慢性荨麻疹,,慢性荨麻疹；皿治林；疗效,1资料与方法,2结果,3讨论
【摘要】 目的 探讨皿治林治疗慢性荨麻疹的临床疗效及治疗机制。方法 研究对象为76例慢性荨麻疹患者，疗程结束后按临床疗效标准进行评定和统计。结果 76例患者经28天皿治林治疗后，暂时痊愈率为89%，总有效率100%。治疗前后对比，差异有非常显著性(P<0.01)。结论 皿治林治疗慢性荨麻疹疗效显著，不良反应发生率低，症状轻微，安全性较高。其治疗机制主要是皿治林具有独特的抗组胺和抗其他炎症介质的双重作用；同时可抑制活化的肥大细胞释放组胺，抑制炎性细胞的趋化作用，抑制变态反应时细胞间黏附性分子-1的释放，是一种强效、长效和高度选择性的H1受体拮抗剂。【关键词】 慢性荨麻疹；皿治林；疗效
Clinical effects of mizolastine on patients with chronic urticaria
LUO Zhi-guang,HE Qian,WU Liang-cai,et al.
Department of Otolaryngology,Xixiang Peoples Hospital,Baoan District, Shenzhen 518102,China
【Abstract】 Objective To study the clinical efficacy and mechanisms of mizolastine on patients with chronic urticaria.Methods After being administered mizolastine 10mg daily for 28 days, all the qualified patients with chronic urticaria were evaluated according to the vested standard of clinical efficacy. All the data were analyzed statistically.Results Of the 76 patients with chronic urticaria, 55 patients (89%) recovered temporarily and all the patients (100%) showed improvement. Statistically significant differences were observed between the day 1 and the day 28 after treatment.Conclusion Mizolastine is an effective drug for chronic urticaria.Administration of mizolastine 10mg daily shows good safety and the side-effects are mild.Mizolastine, a new H1-receptor antagonist, is shown to have both antihistaminic and anti-inflammatory effects. It also inhibits the releasing of histamine from rodent mast cells.Mizolastine inhibits the releasing of soluble intercellular adhesion molecule 1 (ICAM-1) and prevents the chemotaxis of the inflammatory cells.In conclusion,mizolastine is a strong-effect, long-term efficacy and highly selective H1-receptor antagonist. ......
您现在查看是摘要页，全文长 6405 字符。